Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial (PREPS MEXICO)
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Aguascalientes, Mexico, 20127
- Pfizer Investigational Site
-
Chihuahua, Mexico, 31238
- Pfizer Investigational Site
-
Estado de México, Mexico, CP 52763
- Pfizer Investigational Site
-
-
D. F.
-
Mexico, D. F., Mexico, CP 06700
- Pfizer Investigational Site
-
-
Guerrero
-
Acapulco, Guerrero, Mexico, 39670
- Pfizer Investigational Site
-
-
Michoacan
-
Morelia, Michoacan, Mexico, CP 58000
- Pfizer Investigational Site
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 64060
- Pfizer Investigational Site
-
Monterrey,, Nuevo Leon, Mexico, 64460
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female who are diagnosed of partial seizure (simple partial, complex partial, partial seizure secondarily generalized) as defined in the international league of epilepsy classification of seizure.
Exclusion Criteria:
- Patients having a treatable cause of seizure, currently receiving vigabatrin, having a progressive neurological or systemic disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Pregabalin
|
150 to 600 mg/day during 21 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Baseline in 28 Day Partial Seizure Rate During Treatment Observation Phase
Time Frame: Week 9 to Week 21 or End of Treatment (early termination)
|
28-day seizure rate (at observation period [obs]) = [(number of seizures obs ) divided by (duration of period based on observed last dosing date and Visit 3 [Week 9] date)] * 28.
Percent change = [(28-day seizure rate obs minus 28-day seizure rate at baseline [b]) divided by 28-day seizure rate b] * 100.
Negative values indicate a decrease in seizure frequency and positive values reflect an increase in seizure frequency.
|
Week 9 to Week 21 or End of Treatment (early termination)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response Ratio (RR)
Time Frame: Week 9 to Week 21 or End of Treatment (early termination)
|
Response ratio (RR) = comparison between baseline 28-seizure frequency with the 12 week observation phase.
RR = [(28-day seizure rate in observation period [obs] minus 28-day seizure rate at baseline [b] ) divided by (28-day seizure rate obs plus 28-day seizure rate b)] * 100.
Range: -100 to 100; negative values for the RR indicate reductions in seizures.
|
Week 9 to Week 21 or End of Treatment (early termination)
|
|
Percent Change From Baseline in 28-Day Partial Seizure Frequency at Week 21
Time Frame: Week 21 or End of Treatment (early termination)
|
Percent change from Baseline = [(28-day seizure rate at 21 weeks minus 28-day seizure rate at baseline [b]) divided by (28-day seizure rate b) * 100.
Negative values indicate a decrease in seizure frequency, positive values reflect an increase in seizure frequency.
|
Week 21 or End of Treatment (early termination)
|
|
Percent Change From Baseline in Seizure Frequency in Participants Who Had <=6 Seizures and >6 Seizures During the Baseline Period
Time Frame: Week 9 to Week 21 or End of Treatment (early termination)
|
Negative values indicate a decrease in seizure frequency; positive values reflect an increase in seizure frequency.
|
Week 9 to Week 21 or End of Treatment (early termination)
|
|
Percent of Seizure- Free Participants During the Treatment Observation Period
Time Frame: Week 9 to Week 21 or Early Termination (end of treatment)
|
Seizure-free = no seizures during observation period (100 percent reduction in seizures from baseline).
|
Week 9 to Week 21 or Early Termination (end of treatment)
|
|
Percent of Seizure Free Participants During the Last 4 Weeks of the Treatment Observation Period
Time Frame: Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)
|
Seizure-free = no seizures during last 4 weeks of observation period (100 percent reduction in seizures from baseline).
|
Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)
|
|
Percent of Participants With >=50% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period
Time Frame: Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)
|
Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)
|
|
|
Percent of Participants With >=75% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period
Time Frame: Week 17 through Week 21 (or Last 4 Weeks of Treatment after Week 9)
|
Week 17 through Week 21 (or Last 4 Weeks of Treatment after Week 9)
|
|
|
Treatment Satisfaction: Patient General Impression to Change (PGIC)
Time Frame: Week 21, LOCF
|
Patient General Impression to Change (PGIC): participant rated instrument to measure participant's change in overall status since beginning study medication on a 7-point scale; range: 1 (very much improved) to 7 (very much worse).
Not done = participant did not complete the PGIC.
|
Week 21, LOCF
|
|
Change From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS)
Time Frame: Week 21, LOCF
|
Participant rated questionnaire to assess sleep quality and quantity; 9-item overall sleep problems index and 7 subscales.
Sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy subscale scores (s) rated 1 (all the time) to 6 (none of the time); transformed s; total range (r): 0 to 100; higher s = greater intensity of attribute; negative values (v) = reduction from baseline (b), positive v = increase from b. Sleep Quantity score r: 0-24 hours.
Higher s = greater quantity of sleep.
Change = (MOS score at observation period minus MOS score at b) divided by MOS score b.
|
Week 21, LOCF
|
|
Change From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS): Optimal Sleep Subscale
Time Frame: Week 21, LOCF
|
Optimal Sleep subscale of the MOS subject rated questionnaire to assess sleep quality and quantity.
Optimal Sleep (1 of 7 subscales) was derived from sleep quantity: average hours of sleep each night during the past week.
Number of subjects with response: YES=1 (optimal sleep: quantity of sleep was 7 or 8 hours per night) or No= 0 (no optimal sleep).
Negative value indicates a decrease in attribute; positive value indicates an increase in attribute.
Change = (MOS score at observation period minus MOS score at baseline [b]) divided by MOS score b.
|
Week 21, LOCF
|
|
Change From Baseline in Hospital Anxiety and Depression Scale (HADS)
Time Frame: Week 21, LOCF
|
Participant rated questionnaire with 2 subscales: HADS-A assesses generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D: state of lost interest and diminished pleasure response (lowering of hedonic tone).
Each subscale has 7 items; range: 0 (no anxiety or depression) to 3 (severe anxiety or depression).
Total score 0 to 21 for each subscale; higher score = greater severity of symptoms.
Negative value = reduction from baseline (b), positive value = increase from b. Change = (HADS score at observation period minus HADS score at b) divided by HADS score b.
|
Week 21, LOCF
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Seizures
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Pregabalin
Other Study ID Numbers
Other Study ID Numbers
- A0081090
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.